Our Specialist Nurses 0800 074 8383
Donate

Active surveillance

On this page  

What is active surveillance?

Active surveillance is a way of monitoring prostate cancer that hasn’t spread outside the prostate (localised prostate cancer), rather than treating it straight away. You might hear it called active monitoring.

If you decide to go on active surveillance, you’ll have regular tests to check on the cancer. You won’t have any treatment unless these tests show that your cancer may be growing, or you decide you want treatment – so you’ll avoid or delay the side effects of treatment. If there are signs your cancer may be growing, you’ll be offered treatment that aims to cure your cancer.

It might seem strange not to have treatment, but localised prostate cancer often grows slowly – if at all – and may have a low risk of spreading. So it may never cause you any problems or affect how long you live. Because of this, you might not need any treatment. Many men on active surveillance won’t need treatment in their lifetime.

Active surveillance isn’t the same as watchful waiting, which is another way of monitoring prostate cancer. Read about the differences between active surveillance and watchful waiting.

Watch Robin's story for one man's experience of being on active surveillance:

Listen to a summary of this page:

Who can go on active surveillance?

Active surveillance is suitable for men with localised prostate cancer that has a low risk of spreading (low risk prostate cancer).

It’s also sometimes suitable for men with intermediate (medium) risk prostate cancer who want to avoid or delay treatment.

If you have more aggressive, high risk prostate cancer, active surveillance won’t be recommended for you. Read about the different treatments for localised prostate cancer.

Your doctor will look at all your test results to see if active surveillance is an option for you. They will also make sure that:

Talk to your doctor or nurse if you have any questions about your test results or treatment options. You can also get in touch with our Specialist Nurses.

What are the advantages and disadvantages?

Advantages

  • As you won’t have treatment while you’re on active surveillance, you’ll avoid the side effects of treatment.
  • Active surveillance won’t affect your everyday life as much as treatment would.
  • If tests show that your cancer might be growing, there are treatments available that aim to cure your cancer.

Disadvantages

  • You might need to have more prostate biopsies which can cause side effects, and which some men find uncomfortable or painful.
  • Your cancer might grow more quickly than expected and become harder to treat – but this is very uncommon.
  • Your general health could change, which might make some treatments unsuitable for you if you did need them.
  • Some men may worry about not having treatment, and about their cancer growing, although many men find they can get on with their daily lives between appointments.

Deciding whether or not to go on active surveillance is a personal choice. What may be important to one person might not be to someone else. If you’re offered active surveillance, there’s usually no rush to make a decision. Speak to your doctor or nurse before deciding whether it’s right for you.

What does active surveillance involve?

You’ll have regular tests to monitor your cancer. The tests you have, and how often you have them, will depend on your hospital. They may include:

The tests aim to find any changes that suggest the cancer is growing. If any changes are found, you can have treatment that aims to get rid of the cancer – such as surgery or radiotherapy.

Will I need treatment in the future?

If the results of the tests show your cancer is growing, you’ll be offered treatment that aims to get rid of the cancer – for example, surgery or radiotherapy.

Some men decide they want to have treatment even though there are no signs of any changes. You can decide to have treatment at any point – if you decide you do want treatment, speak to your doctor or nurse.

Are there any risks with active surveillance?

Changes to your cancer

There’s a chance that your cancer could grow. But the tests used to monitor your cancer aim to find any changes early enough to treat it. And men who have treatment after being on active surveillance can still have treatment that aims to cure the cancer, such as surgery or radiotherapy.

There is a very small chance that the cancer will spread outside your prostate before being picked up, and treatment might not be able to get rid of it completely. This can happen if the tests used in active surveillance miss changes in your cancer. But this isn’t very common.

Sometimes, men diagnosed with low risk prostate cancer actually have a more aggressive cancer that needs treating to stop it spreading outside the prostate. A prostate biopsy only takes small pieces of tissue from the prostate. But prostate cancer grows unevenly, so it’s possible that a biopsy might miss an area of faster-growing cancer. This is uncommon, and you’ll have regular tests to make sure the cancer isn’t growing more quickly than expected.

Research shows active surveillance is a safe way for men with low risk prostate cancer to avoid or delay unnecessary treatment. Men with low risk localised prostate cancer who go on active surveillance have the same chances of living for 10 years or more as men who choose to have treatment with surgery or radiotherapy. It’s important to think about this when deciding whether to have treatment straight away or to go on active surveillance.

Talk to your doctor or nurse if you’re worried about the risk of your cancer growing.

Concerns about not having treatment

Many men with low risk localised prostate cancer choose to go on active surveillance. But active surveillance isn’t for everyone. You might find it difficult not having treatment for prostate cancer, and worry that your cancer will change or spread. Some men on active surveillance decide to have treatment even though there are no signs of any changes in their cancer.

If at any time you decide that you want treatment, talk to your doctor or nurse. You don’t have to stay on active surveillance if you don’t want to.

Changes to your health

There’s a chance that your general health could change, which would make some treatments unsuitable for you if the cancer did grow. For example, if you were to get heart problems, you might not be able to have a radical prostatectomy, as an operation might not be safe for you.

You can lower your risk of many health problems by eating healthily and doing regular exercise. Read more about diet and physical activity.

Are there any side effects?

As you won’t have treatment while you’re on active surveillance, there aren’t any physical side effects. But you might need to have prostate biopsies while you’re on active surveillance, which can cause some short-term side effects.

How is active surveillance different from watchful waiting?

Active surveillance is often confused with watchful waiting, which is another way of monitoring prostate cancer. The aim of both is to avoid having unnecessary treatment, but the reason for having them is very different.

Active surveillance

  • It’s suitable for some men with localised prostate cancer, who can still have treatment that aims to cure their cancer.
  • If you need treatment in the future, it will aim to cure your cancer.
  • It involves more regular hospital tests than watchful waiting, such as prostate biopsies and magnetic resonance imaging (MRI) scans.

Watchful waiting

  • It’s generally suitable for men with other health problems who may be less able to cope with treatments such as surgery or radiotherapy, or if treatment would cause more problems than the cancer itself.
  • If you do have treatment in the future, it will aim to control the cancer and manage any symptoms, rather than aim to cure it.
  • It can be used in men with localised prostate cancer, or in men whose cancer has spread to other parts of the body (locally advanced or advanced prostate cancer).
  • It involves fewer tests than active surveillance. These usually take place at the GP surgery rather than at the hospital.

Questions to ask your doctor or nurse

You may find it helpful to take a list of any questions you have to your next appointment.

  • How often will I have my PSA level checked?
  • Who will check my PSA level and give me the results?
  • How often will I see my doctor or nurse?
  • How often will I have a digital rectal examination (DRE)?
  • Will I need more prostate biopsies – and how often?
  • Will I need to have any scans?
  • How quickly would my PSA level need to rise for you to recommend treatment?
  • What treatments could I have if my cancer grows?
  • What can I do to improve my general health?

Help improve our page

We'd like to ask you two questions about our page.

References

Updated: November 2016 | Due for Review: November 2018

  • List of references  

    • Albertsen PC. Observational studies and the natural history of screen-detected prostate cancer: Curr Opin Urol. 2015 May;25(3):232–7
    • Albertsen PC, Hanley JA, Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA; 2005
    • Bellardita L, Valdagni R, van den Bergh R, Randsdorp H, Repetto C, Venderbos LDF, et al. How Does Active Surveillance for Prostate Cancer Affect Quality of Life? A Systematic Review. Eur Urol. 2015 Apr;67(4):637–45
    • Bul M, Zhu X, Valdagni R, Pickles T, Kakehi Y, Rannikko A, et al. Active surveillance for low-risk prostate cancer worldwide: the PRIAS study. Eur Urol. 2013 Apr;63(4):597–603.
    • Cao Y, Ma J. Body Mass Index, Prostate Cancer-Specific Mortality, and Biochemical Recurrence: a Systematic Review and Meta-analysis. Cancer Prev Res (Phila Pa). 2011 Jan 13;4(4):486–50
    • D’Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280(11):969–74
    • Davies NJ, Batehup L, Thomas R. The role of diet and physical activity in breast, colorectal, and prostate cancer survivorship: a review of the literature. Br J Cancer. 2011 Nov 8;105:S52–73
    • Donovan JL, Hamdy FC, Lane JA, Mason M, Metcalfe C, Walsh E, et al. Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. N Engl J Med [Internet]. 2016 Sep 14 [cited 2016 Sep 14]; Available from: http://www.nejm.org/doi/10.1056/NEJMoa1606221
    • Glass AS, Cooperberg MR, Meng MV, Carroll PR. Role of active surveillance in the management of localized prostate cancer. J Natl Cancer Inst Monogr. 2012 Dec;2012(45):202–6.
    • Hamdy FC, Donovan JL, Lane JA, Mason M, Metcalfe C, Holding P, et al. 10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer. N Engl J Med [Internet]. 2016 Sep 14 [cited 2016 Sep 14]; Available from: http://www.nejm.org/doi/10.1056/NEJMoa1606220
    • Husson O, Mols F, Poll-Franse LV van de. The relation between information provision and health-related quality of life, anxiety and depression among cancer survivors: a systematic review. Ann Oncol. 2010 Sep 24;mdq413
    • Kazer MW, Psutka SP, Latini DM, Bailey DE. Psychosocial aspects of active surveillance. Curr Opin Urol. 2013 May;23(3):273–7
    • Klotz L, Vesprini D, Sethukavalan P, Jethava V, Zhang L, Jain S, et al. Long-Term Follow-Up of a Large Active Surveillance Cohort of Patients With Prostate Cancer. J Clin Oncol. 2015 Jan 20;33(3):272–7
    • Loeb S, Vellekoop A, Ahmed HU, Catto J, Emberton M, Nam R, et al. Systematic review of complications of prostate biopsy. Eur Urol. 2013 Dec;64(6):876–92
    • Mishra SI, Scherer RW, Geigle PM, Berlanstein DR, Topaloglu O, Gotay CC, et al. Exercise interventions on health-related quality of life for cancer survivors. Cochrane Database Syst Rev. 2012;8:CD007566.
    • Mottet N, Bellmunt J, Briers E, Bolla M, Cornford P, De Santis M, et al. Guidelines on prostate cancer. European Association of Urology; 2016
    • National Institute for Health and Care Excellence. Prostate Cancer: diagnosis and treatment. Full guideline 175. 2014
    • Public Health England. Prostate cancer risk management programme (PCRMP): benefits and risks of PSA testing [Internet]. GOV.UK; 2016. Available from: https://www.gov.uk/government/publications/prostate-cancer-risk-management-programme-psa-test-benefits-and-risks/prostate-cancer-risk-management-programme-pcrmp-benefits-and-risks-of-psa-testing
    • Richman EL, Kenfield SA, Stampfer MJ, Paciorek A, Carroll PR, Chan JM. Physical Activity after Diagnosis and Risk of Prostate Cancer Progression: Data from the Cancer of the Prostate Strategic Urologic Research Endeavor. Cancer Res. 2011 May 24;71(11):3889–95
    • Schoots IG, Petrides N, Giganti F, Bokhorst LP, Rannikko A, Klotz L, et al. Magnetic Resonance Imaging in Active Surveillance of Prostate Cancer: A Systematic Review. Eur Urol. 2015 Apr;67(4):627–36
    • Thomsen FB, Brasso K, Klotz LH, Røder MA, Berg KD, Iversen P. Active surveillance for clinically localized prostate cancer--A systematic review: Active Surveillance for Localized PCa. J Surg Oncol. 2014 Jun;109(8):830–5.
    • Trottier G, Boström PJ, Lawrentschuk N, Fleshner NE. Nutraceuticals and prostate cancer prevention: a current review. Nat Rev Urol. 2009 Dec 8;7(1):21–30
    • Van Patten CL, de Boer JG, Tomlinson Guns ES. Diet and Dietary Supplement Intervention Trials for the Prevention of Prostate Cancer Recurrence: A Review of the Randomized Controlled Trial Evidence. J Urol. 2008 Dec;180(6):2314–22
    • Welty CJ, Cooperberg MR, Carroll PR. Meaningful end points and outcomes in men on active surveillance for early-stage prostate cancer: Curr Opin Urol. 2014 May;24(3):288–92.
    • World Cancer Research Fund International. Continuous Update Project report: Diet, Nutrition, Physical Activity and Prostate Cancer [Internet]. 2014. Available from: www.wcrf.org/sites/default/files/Prostate-Cancer-2014-Report.pdf
    • Yacoub JH, Verma S, Moulton JS, Eggener S, Aytekin O. Imaging-guided prostate biopsy: conventional and emerging techniques. Radiogr Rev Publ Radiol Soc N Am Inc. 2012 Jun;32(3):819-37